Clinical Trials Browser

Phase 1 × Esophageal Squamous Cell Carcinoma × spartalizumab × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Phase 1 Completed

185 enrolled

BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT04641871 2024-06-26

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Phase 1 Completed

78 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Cholangiocarcinoma

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

61 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma